ALK and hypophosphatemia: Furthermore, several anticancer treatments can cause hypophosphatemia, including ifosfamide, cisplatin, and tyrosine kinase inhibitors (TKI) such as imatinib, sunitinib, sorafenib, and regorafenib, as well as anaplastic lymphoma kinase (ALK) inhibitors and mammalian target of rapamycin (mTOR) inhibitors, and fibroblast growth factor receptor (FGFR) inhibitors (286, 287).